Preoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008.

2.50
Hdl Handle:
http://hdl.handle.net/10541/69594
Title:
Preoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008.
Authors:
Scott, N A; Susnerwala, Shabbir; Gollins, Simon W; Myint, A Sun; Levine, Edward
Abstract:
OBJECTIVE: Our aim was to determine the range of neo-adjuvant therapy the multidisciplinary team (MDT) currently offers patients with curable (M(0)) rectal cancer. METHOD: A senior oncologist from each of the four oncology centres in north Wales and the north-west of England (approximate target population 8 million - Glan Clwyd, Clatterbridge, Christie and Preston) reviewed his/her understanding of the current evidence of neo-adjuvant therapy in rectal cancer. Then a representative from each centre was asked to identify which of three neo-adjuvant options (no neo-adjuvant therapy, short-course radiotherapy 25 Gy over five fractions and long-course chemoradiotherapy) he/she would use for a rectal cancer in the upper, middle or lower third of the rectum staged by magnetic resonance imaging as being T(2)-T(4) and/or N(0)-N(2). RESULTS: In all cases of locally advanced rectal cancer (T(3a) N(1)-T(4)), oncologists from the four oncology centres recommended long-course chemoradiotherapy before rectal resection. This consensus was maintained for cases of lower third T(3a) N(0) cancers. Thereafter, the majority of patients with rectal cancer are offered adjuvant short-course radiotherapy. CONCLUSION: Neo-adjuvant therapy is less likely to be offered if the tumour is early (T(2), N(0)) and/or situated in the upper third of the rectum.
Affiliation:
Department of Colorectal Surgery, Lancashire Teaching Hospital Trust, Preston, UK. nigel.scott@lthtr.nhs.uk
Citation:
Preoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008. 2009, 11 (3):245-8 Colorectal Dis
Journal:
Colorectal Disease
Issue Date:
Mar-2009
URI:
http://hdl.handle.net/10541/69594
DOI:
10.1111/j.1463-1318.2008.01636.x
PubMed ID:
18637934
Type:
Article
Language:
en
ISSN:
1463-1318
Appears in Collections:
All Christie Publications ; Clinical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorScott, N A-
dc.contributor.authorSusnerwala, Shabbir-
dc.contributor.authorGollins, Simon W-
dc.contributor.authorMyint, A Sun-
dc.contributor.authorLevine, Edward-
dc.date.accessioned2009-06-02T13:57:24Z-
dc.date.available2009-06-02T13:57:24Z-
dc.date.issued2009-03-
dc.identifier.citationPreoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008. 2009, 11 (3):245-8 Colorectal Disen
dc.identifier.issn1463-1318-
dc.identifier.pmid18637934-
dc.identifier.doi10.1111/j.1463-1318.2008.01636.x-
dc.identifier.urihttp://hdl.handle.net/10541/69594-
dc.description.abstractOBJECTIVE: Our aim was to determine the range of neo-adjuvant therapy the multidisciplinary team (MDT) currently offers patients with curable (M(0)) rectal cancer. METHOD: A senior oncologist from each of the four oncology centres in north Wales and the north-west of England (approximate target population 8 million - Glan Clwyd, Clatterbridge, Christie and Preston) reviewed his/her understanding of the current evidence of neo-adjuvant therapy in rectal cancer. Then a representative from each centre was asked to identify which of three neo-adjuvant options (no neo-adjuvant therapy, short-course radiotherapy 25 Gy over five fractions and long-course chemoradiotherapy) he/she would use for a rectal cancer in the upper, middle or lower third of the rectum staged by magnetic resonance imaging as being T(2)-T(4) and/or N(0)-N(2). RESULTS: In all cases of locally advanced rectal cancer (T(3a) N(1)-T(4)), oncologists from the four oncology centres recommended long-course chemoradiotherapy before rectal resection. This consensus was maintained for cases of lower third T(3a) N(0) cancers. Thereafter, the majority of patients with rectal cancer are offered adjuvant short-course radiotherapy. CONCLUSION: Neo-adjuvant therapy is less likely to be offered if the tumour is early (T(2), N(0)) and/or situated in the upper third of the rectum.en
dc.language.isoenen
dc.subjectRectal Canceren
dc.subjectNeo-Adjuvant Therapyen
dc.subjectConsensusen
dc.titlePreoperative neo-adjuvant therapy for curable rectal cancer--reaching a consensus 2008.en
dc.typeArticleen
dc.contributor.departmentDepartment of Colorectal Surgery, Lancashire Teaching Hospital Trust, Preston, UK. nigel.scott@lthtr.nhs.uken
dc.identifier.journalColorectal Diseaseen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.